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Effects of sulfonylureas, a-endosulfine counterparts, on
glomerulosclerosis in type 1 and type 2 models of diabetes.
Background. Previously, we showed the expression of a
unique sulfonylurea receptor (SUR) and its putative endogenous ligand, a-endosulfine, in mesangial cells and isolated
glomeruli. Further, this ligand was up-regulated by high glucose
concentration. To investigate the possible role of a-endosulfine
up-regulation in diabetes, we administered sulfonylureas, the
exogenous ligands of SUR, to diabetic animals.
Methods. In streptozotocin-induced, insulin-deficient, diabetic rats, glomerulosclerosis, albuminuria, glomerular expression of fibronectin mRNA, and glomerular filtration rate (GFR)
were studied for various periods up to 36 weeks. Several rat
groups received either glibenclamide or tolazamide during the
entire study period. Also, glomerulosclerosis and albuminuria
were determined in insulin-resistant db/db mice, at 26 weeks of
treatment with tolazamide.
Results. Sulfonylureas did not improve hyperglycemia or reduce glycosylated hemoglobin levels. In insulin-deficient diabetic rats, sulfonylureas significantly decreased the degree of
glomerulosclerosis and completely reversed the enhanced albumin excretion. Also, glibenclamide reduced diabetes-induced
glomerular overexpression of fibronectin mRNA. Because
glibenclamide may improve the afferent arteriolar dilatation of
diabetes, thereby reducing glomerular hyperfiltration, its effect
on GFR was determined. Glibenclamide did not alter glomerular hyperfiltration or renal hypertrophy, regardless of the
intensity of hyperglycemia. Finally, in insulin-resistant mice, tolazamide did not alter the extent of diabetic glomerulosclerosis
or increased albuminuria.
Conclusion. Long-term treatment with sulfonylureas completely prevents glomerular injury in insulin-deficient diabetes
in rats. However, this protective effect is not demonstrable in an

insulin-resistant model of the disease. We postulate that mesangial a-endosulfine up-regulation in the hyperglycemic milieu of
insulin-deficient diabetes may retard glomerular extracellular
matrix formation and mesangial expansion.

Sulfonylureas act on adenosine triphosphate (ATP)sensitive K+ channels (K ATP ). The membrane-bound
pancreatic b cell K ATP has been most extensively studied
and represents the “classic” KATP [1–3]. Classic K ATPs
consist of two structurally unrelated subunits: a potassium pore and a sulfonylurea receptor (SUR). The pore
belongs to the Kir6.x subfamily of weak inwardly rectifying K+ channels while SUR is a member of the ATPbinding cassette (ABC) superfamily [4, 5]. Functional b
cell KATPs are tetradimers of Kir.6.2/SUR1 [6] in which
Kir6.2 confers K ATP inhibition by ATP and SUR increases pore sensitivity to ATP, and regulates channel activation by magnesium adenosine diphosphate (MgADP)
and sulfonylureas [3]. Thus, sulfonylurea binding to SUR
inhibits the channel and closes the ion pore. The consequent cell membrane depolarization and Ca2+ influx
through voltage-gated channels mediates insulin secretion.
Nearly 90% of the cellular K ATPs are not localized to
the plasmalemma, but to the endoplasmic reticulum, mitochondria, and secretory granules [7–10]. Consequently,
nearly 70% of all sulfonylurea binding is cytosolic, and
this intracellular locus of action of K ATP appears to be an
important determinant of the action of sulfonylureas [11].
Notably, the sulfonylurea membrane-binding site of the
b cell K ATP is cytosolic, implying the requisite membrane
translocation of exogenously applied sulfonylurea to invoke its action [12] and these observations reconcile the
greater potency of the more highly lipophilic sulfonylurea
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compounds [13, 14]. Thus, all SUR ligands are intracellular.
The extrapancreatic SUR isoforms are the low-affinity
SUR2 isoforms SUR2A and SUR2B [15–17]. SUR2B is
widely expressed in the kidney, particularly in proximal
tubule, ascending limb, and the collecting duct where
it presumably mediates, in part, K+ transport [18–20].
In addition, high- and low-affinity sulfonylurea-binding
components are also present in isolated, metabolically
active glomeruli [21]. In regard to glomerular vascular reactivity, the sulfonylurea glibenclamide reverses
the hypocontractility of diazoxide-dilated afferent arterioles via K ATP activation [22], and in streptozotocininduced diabetic animals, glibenclamide produced a
concentration-dependent decrease in the pathologically
exaggerated afferent arteriolar diameter [23]. Therefore,
sulfonylureas may potentially induce renal metabolic and
functional effects that include amelioration of diabetic
glomerular hypertension.
Pharmacologic studies have demonstrated the diversity of K ATP among various tissues, according to their
sulfonylurea affinity and sensitivity to K+ channel openers [24]. These heterogeneous functional characteristics
are based upon differing complexations of Kir6.x and
SUR isoforms. Recently, we characterized a functional
rat mesangial K ATP containing a previously undescribed
rat mesangial SUR2 splice variant [25, 26]. Expression of
this novel mesangial SUR2 protein was shown in primary
and cloned mesangial cell lines (16KC2) with a specific
antibody that reacted with the common C-terminal epitope of SUR2A and SUR2B.
a-Endosulfine, a putative endogenous ligand of SUR,
has been recently isolated [27, 28]. The gene encoding
this protein (ENSA) is constitutively expressed in many
tissues [29, 30], and a-endosulfine represents one of a
family of neuronal cyclic adenosine monophosphate
(AMP)-regulated phosphoproteins (ARPPs). These proteins are without known enzymatic activity, but possess
characteristics common to intracellular proteins that alter the activities of enzymes involved in signal transduction [e.g., calmodulin and the protein kinase A inhibitor
(Walsh inhibitor) protein kinase I] [31]. Of these ARPPs,
two closely related isoforms have been characterized by
apparent molecular mass (ARPP-16 and ARPP-19) [31],
and these are capable of competitive inhibition of sulfonylurea binding to its target tissues [29, 30]. To date,
only the ARPP-19/e, a-endosulfine, has been well characterized, although its actions remain largely unknown
[31]. It has been proposed that a-endosulfine does not
mediate its actions in an autocrine or paracrine fashion
but by regulating intracellular signaling [32–34].
In recent work, we have demonstrated the ENSA and
a-endosulfine expression in rat glomeruli and cultured
rat mesangial cells [35]. Further, gene and protein expression were up-regulated in parallel during the exposure of
mesangial cells to a high glucose concentration. There-
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fore, glomerular cells express all the components of an
a-endosulfine/K ATP system that is regulatable by glucose.
In the present study, the potential glomerular effects of aendosulfine in vivo have been explored by mimicking its
up-regulation by the chronic administration of a sulfonylurea. Because sulfonylureas are not expected to enhance
insulin secretion in diabetes induced by pancreatic b-cell
injury with streptozotocin, this experimental model offered the opportunity of studying the direct glomerular
effects of these drugs in the absence of the confounding
metabolic effects of hyperinsulinemia. In addition, since
sulfonylureas are extensively used in the treatment of
type 2 diabetes, their effects in an insulin-resistant animal
model of this disease, db/db mice, were also investigated.
METHODS
Materials
Streptozotocin, glibenclamide, tolazamide, fluorescein
isothiocyanate (FITC)-inulin, dextran T-40, ribonucleoside vanadyl complex, and total glycated hemoglobin
kits (#442) were purchased from Sigma Chemical Co.
(St. Louis, MO, USA). Novolin N (NPH) (human insulin
isophane suspension) and Linplant insulin implants
were purchased from Novo Nordisk Pharmaceutical Industries (Clayton, NC, USA) and Linshin Canada Inc.
(Scarborough, Ontario, Canada), respectively. Methohexital (Brevital ) and isofluorane (Forane ) were
obtained from Eli Lilly & Co. (Indianapolis, IN, USA)
and Baxter (Deerfield, IL, USA), respectively. Albuminuria was assessed with the Nephrat and the Creatinine
Companion kits obtained from Exocell Inc. (Philadelphia, PA, USA). Rabbit antirat albumin antibody was
purchased from ICN Biomedical (Aurora, OH, USA).
Ambion (Austin, TX, USA) supplied the RNase inhibitor
SUPERaseIN. Qiagen Inc. (Valencia, CA, USA) provided the following kits for mRNA purification and quantification: RNeasy Mini Kit, RNase-free DNase Set, and
Quantitect Probe RT-PCR Kit. Primers and probes were
purchased from TIB-Molbiol LLC (Adelphia, NJ, USA).
Animals
Simonsen Laboratories (Gilroy, CA, USA) and Jackson Laboratories (Bar Harbor, ME, USA) supplied the
rats and mice, respectively. Studies were carried out according to protocols approved by the Institutional Animal Care and Use Committee of Henry Ford Health
Sciences Center. Insulin-deficient diabetes was induced
in male Munich-Wistar rats at age 4 to 5 weeks old by a
single intravenous dose of 55 mg/kg streptozotocin, dissolved in sodium citrate buffer-acidified normal saline,
via the dorsal penile vein. This dose of streptozotocin results in significantly impaired ability to produce insulin
and moderate to severe hyperglycemia. Long-term survival in most animals occurs without insulin treatment.
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Control animals received the same volume of solution
vehicle. Postprandial (morning) blood glucose and body
weight measurements were obtained twice weekly for 2
weeks then once every 3 to 4 weeks during the rest of
the study. In renal function and gene expression studies, a blood sample was obtained for determination of
glycosylated hemoglobin at the completion of the observation period. Genetically diabetic male obese mice
(C57BLKS db/db) and their nondiabetic heterozygous
lean controls (db/+) entered the study at 4 weeks old,
when obesity and hyperglycemia become evident in the
diabetic group. Blood glucose measurements were obtained during weeks 3 to 4 and at conclusion of experiments.
Treatment protocols
Group 1 rats not regularly treated with insulin. The
goal was to maintain a chronic significant hyperglycemia,
ranging from 350 to 500 mg/dL. Rats in group 1 were used
as diabetic controls in renal function studies, in glomerular gene expression quantification studies at 14 and 22
weeks of diabetes, respectively, and in histologic studies at 36 weeks after disease induction. Since glomerular hyperfiltration has been reported at various intervals
between 1 and 44 weeks [36, 37] after streptozotocin injection, renal functional changes and hypertrophy were
expected to be well established by 14 weeks of diabetes,
when there is no significant glomerular injury. Similarly, a
period of 22 weeks was selected for gene expression quantification because glomerular extracellular matrix mRNA
expression has been reported to be increased between 16
and 24 weeks of experimental diabetes in rats and before
the onset of glomerulosclerosis [38, 39]. Histologic studies were designed to evaluate the initial manifestations of
morphologic glomerular disease. Although mesangial expansion is morphometrically detectable at 24 weeks after
induction of the disease [40], a difference in the prevalence of glomerulosclerosis between diabetic animals and
age-matched controls has only been reported by light microscopy at 38 to 56 weeks of the disease in animals partially treated with insulin [41, 42]. Histologic studies were
not carried out at longer periods of diabetes because after
36 weeks there is a rapid decline in the survival of animals
not regularly treated with insulin.
Although the dose of streptozotocin employed resulted
in hyperglycemia levels that were within the desired
range without insulin administration, 15% of the animals
presented, a twice-confirmed blood glucose level of 600
mg/dL or greater during the last 4 to 8 weeks of the study.
To maintain a similar degree of hyperglycemia in all animals and to avoid malnutrition and weight loss during
long-term diabetes, these severely hyperglycemic animals
received a single, sustained-release subcutaneous insulin
implant (one third of a 7 mm long cylindric Linplant .
This implant reduced blood glucose to levels of 350 to

450 mg/dL for the remainder of the observation period.
All other animals did not receive insulin at any time during the study.
Animals in group 1 were divided into the following
treatment groups: (1) diabetic rats treated with the sulfonylurea tolazamide, (2) diabetic rats treated with the
sulfonylurea glibenclamide, (3) diabetic rats given the
same volume of vehicle, and (4) age-matched control
rats given the same volume of solution vehicle. As part
of this vehicle, animals in all groups received a total of
40 lL/day of dimethyl sulfoxide (DMSO). All animals
received sulfonylureas or the solution vehicle by daily
gavage from day 2 after injection of streptozotocin or
acidified saline. Sulfonylureas were suspended in DMSO,
further diluted in water and given as a 0.5 mL single
daily dose. Tolazamide and glibenclamide were administered either in doses within the human pharmacologic
ranges of 14 mg/kg and 0.28 mg/kg, respectively, or at
ninefold greater amounts (128 mg/kg and 2.52 mg/kg, respectively).
Group 2 rats regularly treated with insulin to induce
moderate hyperglycemia. The goal was to induce a moderate chronic hyperglycemia ranging from 220 to 320
mg/dL. This was achieved by daily subcutaneous administration of 3 to 7 U of Novolin N insulin. Rats in
group 2 were used in renal function studies. Animals
were divided into the following treatment groups: (1) diabetic rats treated with 0.28 mg/kg glibenclamide, and (2)
diabetic rats given the same volume of vehicle. Glibenclamide and solution vehicle were administered by gavage as above.
Group 3 insulin-resistant diabetic db/db mice not treated
with insulin. The goal was to maintain significant chronic
hyperglycemia. No animals required insulin administration as blood glucose concentrations remained lower than
600 mg/dL. Animals in group 3 were used for histologic
analysis and albuminuria determinations at 18 and 26
weeks after study entry. Light microscopy studies were
carried out at these periods of diabetes because previous
observations by others only detected minimal mesangial
expansion at shorter intervals (10 to 12 weeks) [43, 44].
Treatments were initiated at the second week after entry
into the study and maintained for the duration of the experimental period. Mice were divided into the following
groups: (1) diabetic tolazamide-treated by gavage with
14 mg/kg or 128 mg/kg of the drug dissolved in 0.1 mL of
vehicle, (2) diabetic treated with the same volume of drugsolution vehicle, and (3) age-matched, lean heterozygous
controls, gavaged with 0.1 mL vehicle.
Glomerular microdissection and quantitative reverse
transcription-polymerase chain reaction (RT-PCR)
Rat glomeruli were microdissected from the left renal
cortex for total RNA isolation, according to a modification of a previously described method [45]. Following
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isofluorane/oxygen anesthesia, retrograde perfusion of
left kidneys with 50 mL of ice-cold Hank’s balanced salt
solution (HBSS), containing 3.2% dextran T40, was carried out via a needle placed in the abdominal aorta below
the renal arteries. Four sagittal slices from the left kidney
were obtained and placed in 0.8 lm pore-filtered, ice-cold
HBSS containing 5% ribonucleoside vanadyl complex. A
total of 160 glomeruli were microdissected in less than
25 minutes and transferred into 50 lL of sterile,
phosphate-buffered saline (PBS) containing 2 U/lL of
RNase inhibitor. Following the addition of 350 lL of
lysis buffer (buffer RLT) (RNeasy Mini Kit), samples
were rapidly homogenized twice with 15 seconds with
a rotor-strator homogenizer fitted with a 5 mm diameter
probe (Omni lH Micro Homogenizer) (Omni International Inc., Warrenton, VA, USA) and stored at −70◦ C.
Total glomerular RNA was isolated from glomerular
homogenates using the Qiagen’s RNeasy Mini Kit, according to the manufacturer’s instructions. This isolation
included an on-column DNase digestion step. RNA was
stored at −70◦ C prior to RT-PCR.
Rapid cycle, real-time, quantitative RT-PCR was carried out using the Roche LightCycler (Roche Molecular Biochemicals, Indianapolis, IN, USA), in a multiplex,
asymmetric reaction [46]. In this method, a one-step protocol was followed with the RT and PCR reactions carried out sequentially in the same reaction capillary. A
commercially available reaction mix was used (QuantiTectTM Probe RT-PCR) supplemented with 2.5 U of Hot
Star Taq DNA polymerase (Qiagen Inc.) [47]. In multiplex reactions, mRNA templates of interest, fibronectin
and b-actin mRNA, were simultaneously amplified with
specific primers following reverse transcription. Product
formation was detected by fluorescence resonance energy transfer (FRET) reactions, using sequence-specific
pairs of hybridization probes labeled either with fluorescein or with one of two different acceptor dyes (LC-Red
640 and LC-Red 705). All primers were specifically designed for intron-exon splice regions thereby preventing
any possible genomic DNA amplification. b-actin was selected as the gene of reference because of the proven
stability of its expression in diabetic glomeruli [48].
Primers and probes were for fibronectin, 5 -GAGCCTT
CACACATCACCAAGTA, 5 -CATCTCCTTCCTCGC
TCAGTT, 5 -CAAAGCGAGTCACTTCTTGGTGCC
C, and 5 -LC-Red 640-TACTGCTGGATGCTGATGA
GCTGTCCC; for b-actin, 5 -ACCCACACTGTGCCC
ATCTA, 5 -GCCACAGGATTCCATACCCA, 5 -GCC
ACGCTCGGTCAGGATCTTCAT, and 5 -LC Red 705AGGTAGTCTGTCAGGTCCCGGCCA. Values were
calculated as arbitrary units according to results obtained
from standard curves obtained with total renal cortex
RNA, and final data was expressed as the fibronectin
mRNA/b-actin mRNA ratio in the same reaction. All
samples were analyzed in triplicate.

557

Renal function
Conscious, unrestrained rats had glomerular filtration
rates (GFRs) determined by a nonradioisotopic method
that combined previously described techniques [49, 50].
Osmotic minipumps, containing 10 mg/mL of FITCinulin diluted in PBS, were implanted subcutaneously
in rats under 37.5 mg/kg Brevital anesthesia. These
minipumps have a nominal continuous infusion rate of 10
lL/hour over 7 days, delivering 1.67 lg/minute of FITCinulin. Two days after minipump implantation, rats were
placed in metabolic cages, acclimatized for 24 hours and
then two successive 24-hour urine collections were obtained. Following washing of rat tails to remove any urinary contamination, tail vein blood samples (80 lL) were
obtained before and after each urine collection. Plasma
and urine samples were buffered by an equal volume of
1 mmol/L Hepes (pH 7.4). Inulin concentrations were
determined in duplicate, 10 lL samples by measuring fluorescence at wavelength of 480 nm, using the real-time
fluorimetry function of the LightCycler. Standard solutions of FITC-inulin in PBS yielded linear fluorescence
between 1 lg/mL and 20 lg/mL. Plasma and urine blanks
were included to correct for background fluorescence.
GFR was calculated according to the excretion rate and
mean plasma concentration of FITC-inulin. Final results
were the mean value of the two urine and plasma collection periods. Kidneys were weighed at the conclusion of
the study.

Renal histology
Rat and mouse kidneys were perfused as above, except
that perfusion lasted for 2 minutes with HBSS perfusate
at 37◦ C. In addition, perfusion volumes were reduced to
one tenth in mice. Also, immediately following this initial
period, a second perfusion with Tyrode’s buffer (pH 7.4),
containing 22.5% dextran T-40 and 3.7% paraformaldehyde at 37◦ C, was carried out for 3 minutes for in situ fixation of the tissue. The left kidney was then removed and
three, 1 mm thick slices, perpendicular to the longest kidney axis, were obtained and placed in 3.7% paraformaldehyde in PBS at 4◦ C. Tissue slices were embedded in paraffin and 4 lm sections stained with periodic acid-Schiff
(PAS). The degree of mesangial expansion and glomerulosclerosis was semiquantitatively evaluated according to
a scoring system [51]. Three observers, masked as to the
origin of the sample, independently scored the degree
of mesangial expansion or sclerosis on a scale of 0 (no
lesion), 1+ (minimal mesangial expansion), 2+ (evident
mesangial expansion and/or basement membrane thickening), 3+ (marked mesangial expansion with occasional
sclerosed lobules), and 4+ (sclerosis involving most of
the glomerular tuft). Results were expressed as prevalence of sclerosis (number of glomeruli with ≥2+ sclerosis
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Table 1. Characteristics of the rat experimental groups included in histologic studiesa
Control

Group Treatment
Final number
Blood glucose
(9 months mean ± SE)
Final weight

Diabetic

None

None

Tolazimide
(14 mg/kg)

Tolazamide
(128 mg/kg)

Glibenclamide
(0.28 mg/kg)

Glibenclamide
(2.52 mg/kg)

14
94 ± 1.3b

57
422 ± 9.6

22
416 ± 7.7

21
434 ± 6.7

21
409 ± 6.8

24
391 ± 7.0c

279 ± 5.8b

222 ± 7.0d

219 ± 4.8d

231 ± 6.4d

237 ± 4.4d

386 ± 5.3

Values are mean ± SE.
Blood glucose concentration and body weight in all diabetic groups vs. control (P < 0.0001).
Blood glucose concentration vs. nontreated diabetic group (P = 0.013).
d
Body weight vs. nontreated diabetic group (P < 0.001).
a

b
c

divided by the total number of glomeruli scored in a given
specimen).
Enzyme-linked immunosorbent assay (ELISA) and
immunoblotting of urinary proteins
Rat and mouse urinary albumin was determined
from aliquots of 24-hour urine collections by a colorimetric direct competitive ELISA (Nephrat ). In rats,
urinary protein identification was carried out in pooled
collections from four animals in each experimental group
that were dialyzed against PBS and concentrated in
CentriprepTM -10 concentrators (Amicon, Beverly, MA,
USA). Equal amounts of concentrated protein (20 lg)
were dissolved in Laemmli sample buffer and resolved by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on Tris-glycine, 7.5% acrylamide gels,
with proteins identified by Coumassie Blue staining. In
parallel gels, resolved proteins were also transferred to a
polyvinyldene fluoride (PVDF) membranes and blocked
with TBS-T (Tris-buffered saline, pH 7.4, containing
0.05% Tween-20 and 5% skimmed milk powder). Membranes were incubated overnight at 4◦ C with antirat
albumin antibody, diluted in TBS-T. Bound antibody
detection was carried out using the enhanced chemiluminescence (ECL) analysis system (Amersham Pharmacia Biotech UK, Little Chalfont, Buckinghamshire,
England).
Chemical analyses
Urinary creatinine was determined using the Creatinine Companion , a colorimetric modified alkaline picrate method. The percent glycated hemoglobin content
was determined in hemolyzed whole blood samples by
affinity column separation. Total protein was quantified
with the BCA Protein Assay Kit (Pierce, Rockford, IL,
USA).
Statistical analysis
The main statistical analyses were carried out using
the StatView 5.0.1 software (Abacus Concepts Inc.,
Berkeley, CA, USA). Interrater reliability for the mean

from three raters [52] was computed using a SAS macro
(INTRACC) (SAS Institute, Cary, NC, USA). Except
where indicated, results were expressed as mean ± SE
and analyzed by analysis of variance. If significant differences were found among groups, between group comparisons were made with post-hoc testing by Fisher’s
protected least significant difference (PSLD) test, with
significance determined at the 5% level.

RESULTS
Effects of sulfonylureas on the development
of glomerulosclerosis in insulin-deficient diabetes
To investigate the effects of sulfonylureas on the development of diabetic glomerulosclerosis independently
of glycemic control, streptozotocin-diabetic rats were
allowed to remain substantially hyperglycemic during
continued tolazamide or glibenclamide treatment after
disease induction. These compounds are differentiated
by their degrees of lipophilicity that presumably regulate
cell membrane translocation and association with cytoplasmic binding sites [14]. All diabetic animals demonstrated a fourfold increase in their 36-week mean blood
glucose concentration over control values (Table 1). All
animals gained weight during the study period but, as expected, the weight gain was less in diabetic groups than in
controls. Sulfonylurea treatment did not improve blood
glucose levels or body weight gain in diabetic animals
as compared to the nontreated diabetic control group
(Table 1). Only animals treated with high-dosage glibenclamide demonstrated a small (8%) improvement in
glycemia over that in nontreated diabetic rats.
In addition to glomerular mesangial expansion,
basement membrane thickening and lobular sclerosis,
nontreated diabetic animals demonstrated occasional
glomerular vascular hyalinosis and intratubular proteinaceous casts. However, there was only minimal focal interstitial disease. The total number of glomeruli scored
per animal by the three observers was 360 ± 71 (mean,
SD) and similar in all experimental groups. There was
a high overall reliability for the three observers averaged together (interrater reliability coefficient 0.88).
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Effects of sulfonylureas on the glomerular expression
of fibronectin mRNA in insulin-deficient diabetes
Additional evidence of a salutary effect of sulfonylureas in the prevention of glomerular injury was sought
during an earlier period of diabetes when glomerulosclerosis is presumed to be absent. At 22 weeks of diabetes, glomerular fibronectin mRNA expression was
increased over that in age-matched controls, suggesting
its increased synthesis (Fig. 4). These diabetic animals
presented significant hyperglycemia as compared to controls (P < 0.0001). As before, in these animals, treatment
with glibenclamide during the entire period of diabetes
did not improve the level of hyperglycemia (control 86 ±
1.4 mg/dL; diabetic 425 ± 8.9 mg/dL; and diabetic +
glibenclamide 424 ± 7.6 mg/dL) (mean ± SE). In addition, the increased fraction of glycosylated hemoglobin
in diabetic animals (P < 0.0001) was also unaltered by the
administration of glibenclamide (control 5.4 ± 0.2%; diabetic 12.9 ± 0.4%; and diabetic + glibenclamide 13.2 ±
0.5%) (N = 22 to 40) (mean ± SE). However, treat-

% Sclerosis, ≥2+

80

*

60

Sclerosis
†

†
‡

40

†
‡

†
‡

20

0
* P = 0.024 vs. control
† P < 0.001 vs. diabetic control
‡ P < 0.005 vs. control
Albumin/Creatinine, mg/dL:mg/dL

The total number of scores generated by all observers
was 53,730. As compared to age-matched normal controls, 36-week diabetic, nontreated animals presented a
significant increase in the degree of glomerulosclerosis
(Fig. 1). The prevalence of glomerulosclerosis was significantly less in the diabetic groups treated with tolazamide or glibenclamide than in nontreated diabetic
animals (Figs. 1 and 2). Further, this reduction in glomerulosclerosis appeared to be more accentuated in the groups
treated with the higher dosages, particularly in the tolazamide group. Notably, diabetic animals treated with
glibenclamide or high-dosage tolazamide demonstrated a
significantly lower prevalence of sclerotic glomeruli than
normal, age-matched controls (Fig. 1).
Urinary albumin excretion was significantly increased
in diabetic animals as compared to age-matched controls
(Fig. 1). In consonance with the histologic observations,
excessive albumin excretion was fully normalized in all
diabetic groups treated with sulfonylureas (Fig. 1). A recent study has emphasized the possible underestimation
of urinary albumin in streptozotocin-diabetic rats as result of low-molecular-weight albumin fragments not detected by radioimmunoassay [53]. Thus, there was the
theoretical possibility that, due to a modification of the albumin excreted by the sulfonylurea-treated animals, significant amounts of the protein were not detected by the
immunoassay used. To rule this out, concentrated pooled
urine samples from each of the high-dosage, sulfonylureatreated, and control groups were analyzed by PAGE and
immunoblotting. The protein excreted in the nontreated
and sulfonylurea-treated diabetic groups contained a similar fraction of albumin that was immunologically detectable (Fig. 3).

2

*
Albuminuria

1.6
1.2
†
0.8

†

†

†

0.4
0

Control Diabetic
control

14
128
Tolazamide
mg/kg

0.28
2.52
Glibenclamide
mg/kg

Diabetic treated
* P = 0.014 vs. control
† P ≤ 0.003 vs. diabetic control
Fig. 1. Effect of treatment with sulfonylureas on the development of
glomerulosclerosis and albuminuria in long-term diabetic rats. The degree of mesangial expansion, basement membrane thickening, and
glomerulosclerosis were independently assessed by three observers,
who were masked as to the origin of the sample, by light microscopy in
periodic acid-Schiff (PAS)-stained specimens. Studies were carried out
at 36 weeks after induction of diabetes. The degree of glomerular disease was defined on a scale of 0 to 4+. The mean value resulting from the
individual findings by the three observers (percent of glomeruli showing conclusive disease) are presented. Albuminuria data correspond to
samples obtained at the end of the observation period. Each individual
albumin excretion value was the mean of two 24-hour urine collections.
Control, nontreated diabetic, tolazamide-treated, and glibenclamidetreated diabetic animals were the same as those described in Table 1.
Values presented are mean ± SE.

ment with glibenclamide over the entire period of diabetes resulted in a significant reduction in fibronectin
mRNA expression compared to nontreated diabetic animals, although its expression was modestly greater than
in normal controls (Fig. 4).
Effects of sulfonylureas on the renal functional changes
and hypertrophy of insulin-deficient diabetes
Sulfonylureas have been shown to restore the impaired
contractility of glomerular afferent arterioles in diabetes
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Alb. Std.

Diab.-Tolz

A

Diab.-Glib

Diabetic

Control
B

Fig. 2. Effect of treatment with sulfonylureas on diabetic glomerulosclerosis. Perfusion-fixed, periodic acid-Schiff (PAS)-stained kidney
specimens are shown from a nontreated diabetic animal after 36 weeks
of diabetes (A) demonstrating advanced mesangial expansion and sclerosis (+3) and age-matched diabetic animal that had received 0.28
mg/kg glibenclamide daily for the entire duration of diabetes (B) that
revealed only minimal mesangial disease (1+) (original magnification
×200).

[23]. To investigate whether the glomerular protective effects of sulfonylureas could be the result of decreased
glomerular mechanical strain following restoration of
glomerular pressure autoregulation and reduction of diabetic renal hyperfunction, experiments measuring GFR
were carried out in insulin-deficient diabetic rats with and
without treatment with glibenclamide. Studies were carried out at a time when no significant glomerular diabetic
disease is apparent. Since the level of metabolic control
may determine the presence of hyperfiltration, groups of
diabetic animals, incompletely treated with daily insulin
and demonstrating moderate hyperglycemia, were also
studied. Mean blood glucose levels and the fraction of

Fig. 3. Analysis of urinary proteins in long-term diabetic animals
treated with sulfonylureas. Samples were obtained from the same urine
collections presented in Figure 1. Urine collections from four animals
in each group were pooled, dialyzed against phosphate-buffered saline
(PBS) and concentrated. Twenty micrograms of each concentrated urinary protein per sample were analyzed by 7.5% sodium dodecyl sulfatepolyacryalmide gel electrophoresis (SDS-PAGE). Immunodetection
was carried out with purified polyclonal antirat albumin antibody and
enhanced chemiluminescence (ECL) detection.

glycosylated hemoglobin were significantly higher in diabetic animals not treated with insulin than in controls
(Table 2). Incomplete insulin treatment resulted in decreased severity of the metabolic derangement with
blood glucose, glycosylated hemoglobin and weight gains
that were intermediate those of normal age-matched controls and noninsulin treated diabetic animals (Table 2).
Treatment with glibenclamide did not alter the levels of
blood glucose, glycosylated hemoglobin, or final body
weight in either noninsulin-treated or insulin-treated diabetic groups (Table 2).

Fibronectin mRNA/β actin mRNA

Biederman et al: Sulfonylureas in glomerulosclerosis

*

1.0

†
‡

0.8
0.6
0.4
0.2
0

Control

Diabetic

Diabetic
0.28 mg/kg
glibenclamide

* P < 0.001 vs. control
† P = 0.017 vs. diabetic
‡ P = 0.018 vs. control
Fig. 4. Effect of treatment with glibenclamide on diabetes-induced
glomerular overexpression of fibronectin mRNA. Twenty-two weeks
after induction of diabetes the gene expression of fibronectin was determined in samples of microdissected glomeruli by real-time, quantitative
reverse transcription-polymerase chain reaction (RT-PCR). Results are
fibronectin mRNA expression relative to b-actin mRNA expression, determined in the same reaction. One sample, containing 160 glomeruli,
was analyzed per animal. Results are expressed as mean ± SE (N = 21
to 40 animals per experimental group).

Diabetic animals not receiving daily insulin demonstrated marked hyperfiltration and renal hypertrophy
that were unchanged by treatment with glibenclamide
(Fig. 5). Amelioration of the diabetic state by incomplete insulin therapy decreased the magnitude of hyperfiltration and renal hypertrophy. Thus, in these animals, GFR was not significantly different than in controls
(Fig. 5). Again, glibenclamide administration to the
insulin-treated animals did not result in any appreciable
change in either GFR or renal hypertrophy.
Effects of sulfonylureas on the development
of glomerulosclerosis in insulin-resistant diabetes
Sulfonylureas are extensively employed in type 2 diabetes in humans. However, there is a lack of information on their possible effects on the renal disease of
insulin-resistant diabetes in animal models. To explore
the effects of sulfonylureas, db/db mice were continuously treated with tolazamide, in the same dosages described for rats for 26 weeks. Tolazamide, low- or highdosage, did not improve hyperglycemia (Fig. 6). As in
the studies in rats above, renal specimens were scored
for the presence of glomerulosclerosis by three independent observers who were masked as to the origin of the
specimens. The mean total number of glomeruli scored
per animal by the three observers was 160 ± 70 (mean,
SD) without significant differences between experimen-
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tal groups. As before, there was also a high overall reliability for the three observers averaged together (interrater reliability coefficient 0.92). The total number of
scores generated was 13,346. The mean percent of sclerotic glomeruli determined in individual animals by the
three observers was calculated and results are presented
in Figure 6. Obese diabetic mice demonstrated a significantly higher prevalence of glomerulosclerosis compared
to lean controls, and this observation was associated with
enhanced albumin excretion (Fig. 6). In contrast to the effects in insulin-deficient rats, tolazamide did not alter the
degree of glomerulosclerosis, even when it was administered in high dosage. Further, tolazamide administration
did not decrease the elevated levels of albumin excretion.
Additional similar studies were carried out also in a separate group of db/db mice and their controls at 18 weeks
of diabetes (not shown). Although at this shorter period
the degree of glomerulosclerosis and albuminuria in both
diabetic and age-matched control mice were significantly
lower than at 26 weeks, diabetic animals still presented
significantly greater glomerulosclerosis than controls (P
< 0.001). In addition, and as shown in the previous group,
there were no differences between tolazamide-treated
and nontreated diabetic animals (P = 0.85).

DISCUSSION
To envision the potential effects of glomerular aendosulfine up-regulation in diabetes, this study has investigated sulfonylureas as exogenous mimics of this
sulfonylurea-like intracellular protein. A model of
insulin-deficient diabetes offered the opportunity of testing the glomerular effects of these drugs independently of
their action on insulin secretion and in a setting of severe
hyperglycemia. As expected, in streptozotocin-diabetic
rats, sulfonylureas did not alter ambient glycemia levels
or the decreased weight gain at any of the periods of
diabetes studied. In this work, two extensively administered forms of sulfonylureas were used in dosages equivalent to those within the therapeutic range in humans.
In this regard, simply factoring the dosage administered
by body weight is misleading. It has been extensively reported that humans metabolize drugs much slower than
rats with a median rat/human plasma clearance ratio per
unit body weight of 7.18 [54]. Thus, the actual human
equivalent dosage for the 0.28 mg/kg glibenclamide, used
in this study in rats, is only 0.04 mg/kg, approximating a
daily dose of 2.5 mg for the average adult.
Sulfonylureas are notable for their low incidence of
side effects. Tolazamide was developed in 1966 and shown
to have extremely low toxicity in animals with an LD50
of 5 g/kg [55]. Further, in doses of 100 mg/kg/day for 2
years, it did not cause obvious adverse effects in normal
Wistar rats, except for islet b cell hyperplasia. Therefore,
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Table 2. Characteristics of the rat experimental groups included in renal function studiesa
Diabetic

Group
Treatment
Number
Blood glucose mg/dLb
Glycosylated hemoglobin%
Final weight g

Control
None

None

10
93 ± 3.8c
5.0 ± 0.14c
313 ± 5.9c

14
463 ± 12.8
14.6 ± 0.37
246 ± 4.6

Insulin
13
243 ± 22.3d
8.4 ± 0.61d,e
295 ± 6.2d,f

Glibenclamide
(0.28 mg/kg)

Glibenclamide (0.28 mg/kg)
plus insulin

14
464 ± 7.6
14.9 ± 0.46
240 ± 5.8

17
316 ± 11.0d
9.1 ± 0.35d,e
289 ± 4.6d,f

Values are mean ± SE.
Value for each individual animal is the mean of all measurements over the 14-week period of observation.
Blood glucose concentration, glycosylated hemoglobin and body weight in all diabetic groups vs. control (P < 0.001).
d
Blood glucose concentration, glycosylated hemoglobin and body weight in all diabetic insulin-treated groups vs. noninsulin-treated (P < 0.001).
e
Blood glucose concentration and glycosylated hemoglobin in all insulin-treated groups vs. control (P < 0.001).
f
Body weight in all insulin-treated groups vs. control (P < 0.032).
a

b
c

GFR
*

mL/min

5
*

4
3
2
1
0

Kidney Wt
*

*

3

†

†

2
g

it is highly unlikely that the results obtained in this study
are the consequence of confounding toxic side-effects.
At 36 weeks, the degree of mesangial expansion and
glomerulosclerosis was increased in diabetic animals over
age-matched controls. Previous studies documented significantly increased glomerulosclerosis in diabetic rats
only after 12 months of disease [56, 57]. However, in
these studies animals received partial insulin treatment
to maintain moderate hyperglycemia and high survival
rates. Regarding the effect of sulfonylureas on glomerular injury, diabetic animals treated with these drugs had
a significant reduction in the degree of sclerosis, especially in the glibenclamide- and high tolazamide-treated
groups. In these groups, the extent of sclerosis was reduced to levels below control, suggesting that the beneficial effect of sulfonylureas may extend beyond the diabetic state. In previous studies, we reported a progressive
increase in the glomerular collagen content of normal
rats aging from 5 weeks to 2 years [58]. Conceivably, because of pathogenetic similarities between diabetes and
aging [59], sulfonylureas may also act as a inhibitors of
age-related glomerulosclerosis occurring predominantly
in male rats [60, 61].
The mechanism by which sulfonylureas may limit
mesangial matrix deposition remains speculative, however, the reduction of glomerular fibronectin gene expression suggests that inhibition of extracellular matrix
synthesis may play a role. Finally, the beneficial effect
of sulfonylureas on the histologic glomerular disease
was associated with complete normalization of diabeticinduced increased albumin excretion in all sulfonylureatreated groups. In addition, suboptimal immunologic
reactivity for albumin was eliminated as the reason
for this observation. However, albumin excretion in
sulfonylurea-treated animals was not reduced to the levels established by age-matched controls.
Glomerular hypertension and the associated mechanical mesangial strain are considered important
pathogenetic factors in the accumulation of mesangial
extracellular matrix, and these are aggravated by an environment of high glucose concentration [62, 63]. Since

1
0
Control

None Insulin
None Insulin
0.28 mg/kg glibenclamide

Diabetic
* P < 0.009 vs. control
† P < 0.007 vs. Non-insulin treated
Fig. 5. Glomerular filtration rate (GFR) and renal hypertrophy in rats
treated with glibenclamide and suboptimal amounts of insulin. Animals were the same as those described in Table 2. Streptozotocininjected rats were given daily doses of NPH-insulin to maintain partial
metabolic control or left untreated for 14 weeks. Groups of untreated
and insulin-treated animals were also given a daily glibenclamide dose.
GFR was determined in unanesthetized, unrestrained rats according
to the clearance of fluorescein isothiocyanate (FITC)-inulin. Calculations were based on FITC-inulin excretion in two consecutive 24-hour
urine collections and plasma concentration in tail blood samples at the
start, and end of the urine collection periods. The combined weight of
both kidneys was obtained at the conclusion of the experimental period.
Values are mean ± SE.

glibenclamide could reduce glomerular hypertension and
hyperfiltration by normalizing diabetic-induced afferent arteriolar hypocontractility [23], a functional effect
was a plausible mechanism for the glomerulo-protective
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Blood glucose, mg:dL

600

*
*

*

400

200

0
* P < 0.001 vs. control
*

*

*

% Sclerosis, ≥2+

60

40

20

0
* P ≤ 0.025 vs. control

Albumin/creatinine,
mg/dL:mg/dL

1

*
*

0.8
0.6

*

0.4
0.2
0

Control Diabetic
14
128
control
Tolazamide (mg/kg)
* P ≤ 0.022 vs. control
Diabetic treated
Fig. 6. Effect of treatment with sulfonylureas on the development of
glomerulosclerosis in long-term diabetic db/db mice. Obese diabetic
mice and lean normal controls entered the study at 4 to 6 weeks old
and studies performed 26 weeks later. Diabetic animals received by
gavage a daily dose of tolazamide, in the dosages indicated, during the
last 24 weeks of the experimental period. As in studies in rats (Figure
1), the degree of mesangial expansion, basement membrane thickening
and glomerulosclerosis was independently assessed by three observers,
who were masked as to the origin of the sample, in periodic acid-Schiff
(PAS)-stained specimens. The degree of glomerular disease was defined
on a scale of 0 to 4+. The individual findings by the three observers were
combined and presented as the percent of glomeruli showing conclusive
disease. Albuminuria data correspond to samples obtained at the end
of the observation period. Each individual albumin excretion value was
the mean of two 24-hour urine collections. Values presented are mean ±
SE (N = 11 to 17 animals per experimental group).
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properties of sulfonylureas in diabetes. This possibility
was explored in unanesthetized, unrestrained diabetic animals by measuring GFR under conditions of severe or
moderate hyperglycemia. Contrary to historical studies
in anesthetized rats, but in agreement with more recent
observations in conscious animals with blood glucose of
360 to 530 mg/dL [64, 65], it was shown that noninsulin
treated diabetic rats with marked hyperglycemia developed hyperfiltration. Nevertheless, this alteration, and
the concomitant renal hypertrophy was not modified by
glibenclamide administration, regardless of whether animals were receiving suboptimal insulin treatment and
demonstrating milder glomerular hyperfunction and renal hypertrophy. Thus, the preventive effects of sulfonylureas on the development of glomerulosclerosis are
unlikely to be related to improved afferent arteriolar
contractility.
Since sulfonylureas did not diminish hyperglycemia,
diabetic hyperfiltration, or the characteristic renal hypertrophy, the glomerular effects elicited by these drugs
occurred in a setting wherein the major pathogenetic
mechanisms of diabetic glomerular injury were not corrected (i.e., high glucose concentration, glomerular hyperfiltration, and renal hypertrophy [42, 66–71]).
The results of this study suggest that the glomerular
effects of sulfonylureas in diabetes are due to a direct
metabolic effect, possibly by interrupting or modulating signaling pathways through which glucose exerts its
stimulating effects on extracellular matrix synthesis. This
would be in consonance with the postulated mechanism
of action of a-endosulfine. Since activation of the protein
kinase C/mitogen-activated protein kinase cascade plays
a major role in the mediation of the glomerular injurious
effects of high glucose [72, 73], this pathway appears as
a likely target for sulfonylurea action. This postulate is
supported by preliminary results from our laboratory in
mesangial cells in tissue culture treated with low concentrations of glibenclamide [abstract; Cortes P, et al, J Am
Soc Nephrol 14:129A, 2003].
The glomerular effects of long-term sulfonylurea administration suggest that up-regulation of a-endosulfine
expression in mesangial cells may attenuate the stimulating effects of high glucose concentrations on the formation and deposition of extracellular matrix. However, the
interplay between a-endosulfine and its exogenous counterparts remains speculative. An attractive possibility is
that the effects of sulfonylureas are, at least in part, mediated by the up-regulation of mesangial cell ENSA and
a-endosulfine expression (unpublished observations).
The long-term administration of tolazamide did not alter the degree of glomerular disease or albuminuria in
an animal model of type 2 diabetes. However, in this
model, sulfonylureas failed to improve hyperglycemia.
These findings suggest that the glomerular effects of sulfonylureas differ in insulin-deficient and insulin-resistant
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diabetes, unless these drugs effectively improve glucose levels. In agreement with this postulate are results
from controlled clinical studies. The United Kingdom
Prospective Diabetes Study (UKPDS) determined the
incidence of microvascular complications in type 2 diabetic patients that were treated by either conventional
means (dietary modification), intensive therapy with one
of three sulfonylureas (chlorpropamide, glipizide, and
glibenclamide), a biguanide (metformin), or insulin [74,
75] This study demonstrated a reduction in the progression of albuminuria and renal insufficiency in all the intensively treated groups. However, no significant differences
among these groups were shown, suggesting that sulfonylureas do not specifically alter the course of nephropathy
other than by correcting the metabolic state.

CONCLUSION
This study demonstrates that the long-term administration of low-dosage sulfonylureas, particularly
glibenclamide, prevents the development of glomerulosclerosis and albuminuria in experimental, insulindeficient diabetes. This effect takes place independently
of hyperglycemia, glomerular hyperfunction, or renal
hypertrophy. Results suggest that up-regulation of the
mesangial SUR endogenous ligand, a-endosulfine, may
be a suppressor of the glucose-enhanced accumulation of
mesangial matrix. In regard to the potential therapeutic
use of sulfonylureas, clinical testing will be required to
demonstrate that these drugs also prevent nephropathy
in human type 1 diabetes.
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